The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Thursday, August 13, 2026

Subject of the day

XVIVO.ST

Concerning the House

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Sweden · www.xvivogroup.com

The Ledger
LineMar 2025Jun 2025Dec 2025Mar 2026
Revenue$218.59M$178.29M$226.14M$240.96M
Gross profit$160.37M$132.66M$164.08M$171.04M
Operating income$26.57M$7.08M$36.82M$31.94M
Net income-$12.40M$1.57M$31.65M$36.30M
Diluted EPS-0.390.051.011.15
Free cash flow-$15.25M$8.80M$86.93M$65.34M
Quotation

$307.20

+2.20 (+0.7%)

52w hi$307.20
52w lo$160.80
Vol58.78K
As ofAug 13
The Verdict

Hold

Our score +0.23

Short-0.15
Medium+0.35
Long+0.76

computed 2026-08-13

By the Numbers

Xvivo Perfusion AB (publ)

Healthcare · Medical Devices

Market cap$9.73B
Enterprise value$9.55B
Trailing P/E110.36x
Forward P/E52.28x
EV / EBITDA60.34x
P / S (ttm)10.87x
Profit margin9.9%
Return on equity4.1%
Revenue growth+34.0%
Earnings growth+935.1%
Debt / equity5.53
Risk Metrics
Beta vs SPX0.42
Corr SPX0.13
Annual vol52.0%
Annual ret-19.7%
Sharpe-0.38
Max DD-72.0%

Window: 504 trading days (490 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.44
Sector+0.12
Technical+0.00
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$308.80$312.60$303.8058.78K
Aug 12$308.40$310.40$304.20$307.20129.78K
Aug 11$279.20$314.80$279.00$305.00295.81K
Aug 10$279.00$283.00$278.00$281.0052.61K
Aug 7$271.60$283.40$271.40$278.6062.51K